Obturation composition

Patent metadata

Field	Value
Publication number	US-10835452-B2
Application number	US-201815995714-A
Country	US
Kind code	B2
Filing date	Jun 1, 2018
Priority date	Jun 1, 2017
Publication date	Nov 17, 2020
Grant date	Nov 17, 2020

Abstract

A dental composition comprising pre-reacted particulate mineral trioxide aggregate (MTA) dispersed in a hydrogel wherein the content of MTA in the composition is in the range of 20 to 50 percent by weight based on the total weight of the composition.

First claim

The invention claimed is:

1. A dental composition comprising,
a pre-reacted particulate of cured mineral trioxide aggregate (MTA) and/or dental cement in an amount ranging from 20-50% by weight based on the total weight of the composition, wherein the pre-reacted particulate has an average particle size from 0.1 to 100 micrometers;
a hydrogel;
wherein the cured particulate is dispersed in the hydrogel;
wherein the hydrogel includes a polymeric network obtainable by polymerizing a mixture having one or more monomers selected from the group consisting of acrylic acid, acrylamide, vinyl alcohol, and combinations thereof.

2. A dental composition comprising:
a pre-reacted particulate of cured mineral trioxide aggregate (MTA) and/or dental cement in an amount ranging from 20-50% by weight based on the total weight of the composition, wherein the pre-reacted particulate has an average particle size from 0.1 to 100 micrometers;
a hydrogel; and
an organic matrix that includes sodium alginate, pectin, and/or chitosan;
wherein the cured particulate is dispersed in the hydrogel.

3. The dental composition according to claim 2 , wherein the organic matrix is present in an amount of from 30 to 90 percent by weight based on the total weight of the composition.

4. The dental composition according to claim 1 , for use in endodontic treatment of a tooth.

5. The dental composition for use according to claim 4 , wherein the endodontic treatment is selected from indirect and direct pulp-capping and mature and pediatric pulpotomy.

6. The dental composition for use in the according to claim 4 , wherein the endodontic treatment is the obturation of a pulp chamber.

7. The dental composition according to claim 1 , wherein the dental composition:
(i) is bio inductive for cementum,
(ii) stimulates a hard tissue covering areas where a blood supply exists thereby regenerating cementum creates a biological seal;
(iii) does not stimulate an inflammatory process;
(iv) supports tissue regeneration; and/or
(v) is biocompatible with pulp and periradicular tissues while not being cytotoxic in a cured or uncured state.

8. The dental composition according to claim 1 , wherein the composition is antibacterial or antimicrobial due to a pH increase.

9. The dental composition according to claim 1 , wherein the composition will produce hydroxyapatite when exposed to either blood or simulated body fluid.

10. A process for the preparation of a dental composition comprising the steps of:
providing one or more powders selected from the group consisting of a pre-reacted particulate of cured mineral trioxide aggregate (MTA), a dental cement, a portland cement, and mixtures thereof;
(ii) providing one or more liquids selected from the group consisting of Water, water-soluble polymer, surfactants, Phosphate Buffered Saline, 0.09% Saline, and mixtures thereof;
(iii) mixing the one or more powders with the one or more liquids to form a cured mineral trioxide aggregate MTA and/or dental cement;
(iv) milling, the cured MTA and/or dental cement to an average particle size of from 13.1 to 100 micrometer to form a pre-reacted particulate;
(v) dispersing the pre-reacted particulate in a hydrogel matrix for forming a composite composition.

11. The process according to claim 10 , wherein the dental composition:
(i) is bio inductive for cementum,
(ii) stimulates a hard tissue covering areas where a blood supply exists thereby regenerating cementum creates a biological seal;
(iii) does not stimulate an inflammatory process;
(iv) supports tissue regeneration; and/or
(v) is biocompatible with pulp and periradicular tissues while not being cytotoxic in a cured or uncured state.

12. The process according to claim 11 , wherein the composition is antibacterial or antimicrobial due to a pH increase.

13. The process according to claim 11 , wherein the composition will produce hydroxyapatite when exposed to either blood or simulated body fluid.

14. The process of claim 10 , wherein the water-soluble polymer is selected from the group consisting of polyvinyl alcohol, polyvinyl alcohol co-polymer, partially hydrolyzed polyvinyl acetates, polyvinyl-pyrrolidone, hydroxyethyl methacrylate, water-soluble poly-saccharide, polyethylene glycols, polypropylene glycols, and mixtures thereof.

15. The process of claim 10 , wherein the surfactant is selected from the group consisting of alkyl sulfates, fatty acid salts with C 10 -C 24 side chains, alkyl ether sulfates, alkyl sarcosinates, alkyl betaines, sarcosinates, and mixtures thereof.

Assignees

• Dentsply Sirona Inc

Inventors

• Berger Todd Patrick
• Baratz Adam Zachary
• Rose Sheridan Lynn

Classifications

• C08L5/04 Primary

  Alginic acid; Derivatives thereof · CPC title

• A61K6/17

  Particle size · CPC title

• A61K6/56

  Apical treatment · CPC title

• A61K6/816

  comprising titanium oxide · CPC title

• C08L5/06

  Pectin; Derivatives thereof · CPC title